Temozolomide in malignant gliomas: current use and future targets.

Article Details

Citation
Copy to clipboard

Villano JL, Seery TE, Bressler LR

Temozolomide in malignant gliomas: current use and future targets.

Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55. doi: 10.1007/s00280-009-1050-5. Epub 2009 Jun 19.

PubMed ID
19543728 [ View in PubMed
]
Abstract

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

DrugBank Data that Cites this Article

Drugs